Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer
To assess the safety, tolerability, and therapeutic efficacy of BIND-014, a PSMA-targeted docetaxel nanoparticle, in patients with metastatic castration-resistant prostate cancer.
Conducted an interventional clinical trial evaluating BIND-014 docetaxel nanoparticles in patients with metastatic castration-resistant prostate cancer (ClinicalTrials.gov: NCT01812746).
Monitored safety parameters, adverse events, and antitumor activity following targeted nanoparticle administration.
Evaluated clinical response rates and safety outcomes for targeted nanoparticle delivery in metastatic disease.
Specific quantitative safety and efficacy metrics are tracked under clinical trial identifier NCT01812746.